Honigman Advises BioXcel Therapeutics on $14 Million Registered Direct Offering

BioXcel Therapeutics, Inc., a biopharmaceutical company, closed on March 4, 2025 its registered direct offering of (i) 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000,000 shares of common stock and (ii) warrants, exercisable for two weeks after the closing of the offering, to purchase up to an additional 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 4,000,000 shares of common stock, at a combined offering price of $3.50 per share or pre-funded warrant. Gross proceeds from the offering were approximately $14 million, before deducting discounts and commissions and offering expenses.

Honigman advised BioXcel Therapeutics, Inc. in the offering and was led by corporate partners N. Danny Shulman and Emily J. Johns, with associates Isaac Pasha and Cassie J. O'Hagan.

About Honigman

Honigman LLP is an Am Law 200 full-service, general business law firm with more than 350 attorneys counseling clients on complex issues across the country in Chicago, Michigan (Ann Arbor, Bloomfield Hills, Detroit, Grand Rapids, Kalamazoo and Lansing), Washington, D.C. and Israel. Honigman lawyers counsel clients on complex issues in more than 60 areas of law. For more information, visit www.honigman.com.

###